{{product.productLabel}} {{product.model}}
{{#if product.featureValues}}{{product.productPrice.formattedPrice}} {{#if product.productPrice.priceType === "PRICE_RANGE" }} - {{product.productPrice.formattedPriceMax}} {{/if}}
{{#each product.specData:i}}
{{name}}: {{value}}
{{#i!=(product.specData.length-1)}}
{{/end}}
{{/each}}
{{{product.idpText}}}
{{product.productLabel}} {{product.model}}
{{#if product.featureValues}}{{product.productPrice.formattedPrice}} {{#if product.productPrice.priceType === "PRICE_RANGE" }} - {{product.productPrice.formattedPriceMax}} {{/if}}
{{#each product.specData:i}}
{{name}}: {{value}}
{{#i!=(product.specData.length-1)}}
{{/end}}
{{/each}}
{{{product.idpText}}}
... late breast cancer recurrence and survival. NEJM Evid. 2024;3(8):EVIDoa2300267.
Sensitivity: 95 %
... The kit covers key gene mutations such as AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 to detect established and emerging predictive markers, resistance mutations, and frequently occurring genetic alterations in breast ...
... Female breast cancer has now surpassed lung cancer as the leading cause of global cancer incidence in 2020. The elevated incidence rates in higher HDI countries reflect a longstanding ...
... patient follow-up. Breast cancer TPS® has consistently been found to be a good marker for prediction of prognosis and response to therapy. By serial testing, TPS® can be used for therapy control and follow-up of ...
... Immunoassay for in vitro quantitative determination of Cancer Antigen 15-3 (CA15-3) in human serum and plasma, and for clinical application in breast cancer treatment effect and prognosis observation. ...
LINEAR CHEMICALS
Sample volume: min 18.0 ml
... room temperature. It allows, from a single sample, in addition to cytopathological exams, the processing of other molecular tests for STIs. ...
Result display time: 4 h
... significantly increasing the risk of developing breast cancer, ovarian cancer, and other related tumors [1]. About 10% of breast cancer patients [2-3], 10-15% of ovarian ...
SPACEGEN
... your chances of developing breast cancer. But, together they may increase your risk to a point where a proactive approach is recommended. Uniquely powered to assess your risk GeneType for Breast ...
... In Clinic, it is mainly used to observe the curative effect and Prognosis of Breast Cancer. ...
... Multigene prognostic test predicts the probability of metastasis or recurrence, which helps patients make treatment decision. It improves quality of life for cancer patients as preventing them from unnecessary chemotherapy. GenesWell ...
Gencurix
... humans, ERα is encoded by the ESR1 gene (estrogen receptor 1). Hormone receptor (HR)-positive breast cancers account for approximately 70% of all breast cancers. Endocrine therapy ...
... lung cancer patients were associated with PIK3CA mutation, and the mutation patients related with TKI drug resistance. Therefore the detection of PIK3CA gene mutation can effectively guide personalized medication in breast ...
Wuhan YZY MEDICAL Science and Technology
the best suppliers